Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 6/20 | 0.54 |
| ▸ | FLT3 | P36888 | 3/20 | 0.54 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.54 |
| ▸ | GAS6 | Q14393 | 3/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | DNM2 | P50570 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19476315 | 0.86 | MERTK (0.69) | MERTKFLT3TYRO3GAS6MAPK8 | |
| SCHEMBL19477217 | 0.83 | MERTK (0.58) | MERTKFLT3TYRO3GAS6MAPK8 | |
| SCHEMBL19476311 | 0.82 | MERTK (0.58) | MERTKFLT3TYRO3GAS6MAPK8 | |
| SCHEMBL19477227 | 0.81 | HRH4 (0.56) | MERTKFLT3TYRO3GAS6MAPK8 | |
| SCHEMBL19476993 | 0.80 | MERTK (0.56) | MERTKFLT3TYRO3GAS6MAPK8 | |
| SCHEMBL19476313 | 0.80 | MERTK (0.59) | MERTKFLT3TYRO3GAS6MAPK8 | |
| SCHEMBL19476312 | 0.80 | MERTK (0.59) | MERTKFLT3TYRO3GAS6MAPK8 | |
| SCHEMBL19477186 | 0.80 | CCNT1 (0.52) | CCNT1CDK9GRIN2BCYP11B2ACHE | |
| SCHEMBL29501428 | 0.77 | GRIN2B (0.50) | HRH4GRIN2BCYP11B2 | |
| SCHEMBL19476319 | 0.76 | MERTK (0.54) | MERTKFLT3TYRO3GAS6MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| WO-2017181177-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | MERTK 824/4885FLT3 1195/4885TYRO3 3367/4885 |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | MERTK 1304/4885FLT3 1824/4885TYRO3 2895/4885 |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | MERTK 1304/4885FLT3 1824/4885TYRO3 2895/4885 |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | MERTK 824/4885FLT3 1195/4885TYRO3 3367/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | MERTK 3097/4885FLT3 4280/4885TYRO3 4626/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | MERTK 824/4885FLT3 1195/4885TYRO3 3367/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | MERTK 1040/4885FLT3 3735/4885TYRO3 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.